Seaport Therapeutics, Inc.
SPTXUnited States
2 filed reports · 153 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
2 reports · Mar 2026 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 340 | Mar 2026 to Jun 2026 |
Financial data
153 concepts · 340 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial152 concepts · 328 facts · Dec 2024 to Jul 2026
- Accrued liabilities current and noncurrent4 · Mar 2025 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value4 · Mar 2025 to Jun 2026
- Allocated share based compensation expense4 · Mar 2025 to Jun 2026
- Antidilutive securities excluded from computation of earnings per share amount4 · Mar 2025 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax4 · Mar 2025 to Jun 2026
- Earnings per share basic4 · Mar 2025 to Jun 2026
- Earnings per share diluted4 · Mar 2025 to Jun 2026
- Effective income tax rate continuing operations4 · Mar 2025 to Jun 2026
- General and administrative expense (US GAAP)4 · Mar 2025 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Mar 2025 to Jun 2026
- Income tax expense benefit4 · Mar 2025 to Jun 2026
- Interest and other income4 · Mar 2025 to Jun 2026
- Interest income expense nonoperating net4 · Mar 2025 to Jun 2026
- Net income loss4 · Mar 2025 to Jun 2026
- Nonoperating income expense4 · Mar 2025 to Jun 2026
- Operating expenses (US GAAP)4 · Mar 2025 to Jun 2026
- Operating income loss4 · Mar 2025 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent4 · Mar 2025 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax4 · Mar 2025 to Jun 2026
- Other general and administrative expense4 · Mar 2025 to Jun 2026
- Other indirect research and development expenses4 · Mar 2025 to Jun 2026
- Other nonoperating expense4 · Mar 2025 to Jun 2026
- Research and development expense4 · Mar 2025 to Jun 2026
Product1 concepts · 12 facts · Mar 2025 to Jun 2026
- Research and development expense12 · Mar 2025 to Jun 2026
Segments
12 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 12 facts
- Glyph2 BLSD Direct Research And Development Expenses4 · Mar 2025 to Jun 2026
- Glyph Ago Direct Research And Development Expenses4 · Mar 2025 to Jun 2026
- Glyph Allo Direct Research And Development Expenses4 · Mar 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.